Stoke Therapeutics (STOK) is a pre-revenue biotech with EMPEROR Phase 3 readout for zorevunersen — an intrathecal antisense oligonucleotide for Dravet syndrome — due mid-2027. The Q1 2026 call confirmed enrollment closure, released 4-year open-label extension data, and laid out a label strategy the Street hasn't priced.

What the filing says

Screening for EMPEROR is closed. 130 of 150 patients randomized as of May 5; ≈20 remaining in the 8-week screen period, management committed to 150 by June. Cash $411M funds through commercial launch. Rolling NDA Q1 2027, approval target Q4 2027-early 2028.

Pre-specified Vineland Adaptive Behavior Scale data from the open-label extension: p<0.01 across all five sub-domains at years 1, 2, 3, AND 4. Data continues to improve year-over-year, not plateau. 850+ doses administered, no new safety signals.

CEO cited October 2022 FDA multiple-endpoints guidance and 2006 Section 14 guidance, naming SPINRAZA, SKYCLARYS, and QALSODY as precedents for OLE data in the label.

Verification against primary sources

DailyMed labels confirm the precedents but quality varies. SPINRAZA Section 14.3 contains NURTURE single-arm functional milestone data with no cautionary language — the strongest analog. SKYCLARYS and QALSODY use post-hoc / biomarker frameworks with explicit caveat language. STOK's pre-specified, statistically significant Vineland data is structurally closer to NURTURE.

XENE Q1 2026 (2026-05-07): NaV1.1 Dravet program still preclinical, no clinical lead selected; CMO referenced "Stoke's ASO" as the validated comparator. PRAX is SCN2A. TSHA is Rett. No direct Dravet competitor in clinic. Orphan exclusivity extends through ≈2034-2036 from a 2027 launch.

BIIB Q1 2026 (2026-04-29): Singhal listed zorevunersen alongside litifilimab/felzartamab as late-stage registrational catalysts. Partnership remains active despite STOK's own reduced partnership discussion.

Enrollment velocity: STOK 10 months vs FINTEPLA 18-24mo, HRMY ARGUS still enrolling after 18+mo, UCB calling Dravet "more challenged" — materially faster than every comparable Phase 3.

What the market thinks

14 analysts unanimously bullish, mean target $45 (+43%); BTIG $39, Canaccord $60. 21.8% short float, 23 days to cover. IV 77th percentile.

Reverse-engineering market-implied probabilities from current price against state targets (bull-full-label ≈ $81, base-narrow ≈ $45, bear ≈ $12):

$31.50 = P_bull · $81 + 0.28 · $45 + (0.72 − P_bull) · $12
P_bull ≈ 0.15

Market implies P(bull-full-label) ≈ 15-20% vs our 30-45%. The edge is not on probability of trial success — sell-side and our estimate of P(primary hits) agree around 60-70%. The edge is on what happens conditional on the trial hitting.

Why the gap exists

The 4-year OLE data released this quarter; NEJM publication this quarter. The Section 14 precedent inference requires reading actual FDA labels on DailyMed. The competitive moat finding requires reading XENE's call. The Street is implicitly pricing FINTEPLA-class labels ($25-50K/yr) rather than SPINRAZA-class ($300-500K/yr). The cross-ticker synthesis isn't done.

Persistent insider selling Dec 2025-Mar 2026 ($3.3M, 80:1 sell/buy, CEO + GC + two directors + an officer) creates persistent doubt and dampens the willingness to reprice on the Section 14 inference.

Risks (ranked)

1. EMPEROR primary endpoint fails. 30-35% base-rate-adjusted probability (CNS Phase 3 historical 40-50%, modulated down by 4-year OLE durability, BTD, pre-specified endpoints, FDA Plausible Mechanism Framework). Stock collapses to cash + option value (≈$10-12).
2. Vineland Week 52 secondary fails or mixed. Narrow label, premium pricing thesis breaks. Stock $35-55.
3. Insider selling continues or DSMB safety signal disclosed. Information asymmetry concern reinforced.
4. FDA refuses Section 14 OLE inclusion. Label scope narrows even with primary hit; pricing power capped.
5. Biogen partnership economics undisclosed. US co-promotion split could be unfavorable to STOK.

Catalysts

• June 2026 — EMPEROR enrollment completion 8-K
• Late Jul/Aug 2026 — BIIB Q2 earnings call (partnership reaffirmation test)
• Q4 2026 — AES annual meeting, ADOA Cohort 3-4 efficacy
• Q1 2027 — Rolling NDA submission begins
• Mid-2027 — EMPEROR primary endpoint readout

What would change our mind

• DSMB safety signal disclosure → bear case activates immediately
• Continued insider selling at $30+ → information asymmetry concern reinforced
• XENE NaV1.1 IND filing or Phase 1 start by end-2026 → moat narrative weakens
• FDA Type B meeting unfavorable to Section 14 OLE inclusion → label scope narrows
• Cross-ticker contradiction (PRAX safety issue read-across, BIIB drops partnership)

Evidence

Bullish but disciplined. Edge is on the conditional node (P(bull-full-label | primary hits)), not on the binary itself. The insider selling counterweight is real and unresolved.